Chuzhong Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6448059/publications.pdf

Version: 2024-02-01

98 papers 1,261 citations

430874 18 h-index 501196 28 g-index

104 all docs

104 docs citations

104 times ranked 1421 citing authors

#	Article	IF	CITATIONS
1	Radiomic Features on Multiparametric <scp>MRI</scp> for Preoperative Evaluation of Pituitary Macroadenomas Consistency: Preliminary Findings. Journal of Magnetic Resonance Imaging, 2022, 55, 1491-1503.	3.4	6
2	Mid-term follow-up surgical results in 284 cases of clival chordomas: the risk factors for outcome and tumor recurrence. Neurosurgical Review, 2022, 45, 1451-1462.	2.4	13
3	The SF3B1R625H mutation promotes prolactinoma tumor progression through aberrant splicing of DLG1. Journal of Experimental and Clinical Cancer Research, 2022, 41, 26.	8.6	11
4	The clinical application of intraoperative visual evoked potential in recurrent craniopharyngiomas resected by extended endoscopic endonasal surgery. Clinical Neurology and Neurosurgery, 2022, 214, 107149.	1.4	1
5	Endoscopic Endonasal Transsphenoidal Surgery for Recurrent Craniopharyngiomas. Frontiers in Neurology, 2022, 13, 847418.	2.4	4
6	Feasibility of endoscopic endonasal resection of intrinsic third ventricular craniopharyngioma in adults. Neurosurgical Review, 2022, 45, 1-13.	2.4	7
7	LncRNA PCAT6 regulates the progression of pituitary adenomas by regulating the miR-139-3p/BRD4 axis. Cancer Cell International, 2021, 21, 14.	4.1	11
8	Phosphorylation of Pit-1 by cyclin-dependent kinase 5 at serine 126 is associated with cell proliferation and poor prognosis in prolactinomas. Open Chemistry, 2021, 19, 785-793.	1.9	0
9	Up-regulation of the expressions of MiR-149-5p and MiR-99a-3p in exosome inhibits the progress of pituitary adenomas. Cell Biology and Toxicology, 2021, 37, 633-651.	5.3	20
10	A nomogram to predict the progression-free survival of clival chordoma. Journal of Neurosurgery, 2021, 134, 144-152.	1.6	11
11	Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival. Nature Communications, 2021, 12, 757.	12.8	55
12	The Functional Reorganization of Language Network Modules in Glioma Patients: New Insights From Resting State fMRI Study. Frontiers in Oncology, 2021, 11, 617179.	2.8	8
13	The clinical features, recurrence risks and surgical strategies of bone invasive pituitary adenomas. Clinical Neurology and Neurosurgery, 2021, 201, 106455.	1.4	3
14	Clinical Implication of Systemic Immune-Inflammation Index and Prognostic Nutritional Index in Skull Base Chordoma Patients. Frontiers in Oncology, 2021, 11, 548325.	2.8	5
15	Identifying critical proteinâ€'coding genes and long nonâ€'coding RNAs in nonâ€'functioning pituitary adenoma recurrence. Oncology Letters, 2021, 21, 264.	1.8	8
16	Predicting the location of the preoptic and anterior hypothalamic region by visualizing the thermoregulatory center on fMRI in craniopharyngioma using cold and warm stimuli. Aging, 2021, 13, 10087-10098.	3.1	3
17	In Vivo Characterization of Cortical and White Matter Microstructural Pathology in Growth Hormone-Secreting Pituitary Adenoma. Frontiers in Oncology, 2021, 11, 641359.	2.8	2
18	Screening and Identification of Key Microenvironment-Related Genes in Non-functioning Pituitary Adenoma. Frontiers in Genetics, 2021, 12, 627117.	2.3	6

#	Article	IF	Citations
19	Endoscopic Endonasal Surgical Strategy for Skull Base Chordomas Based on Tumor Growth Directions: Surgical Outcomes of 167 Patients During 3 Years. Frontiers in Oncology, 2021, 11, 724972.	2.8	6
20	Proteomics Analysis Identified ASNS as a Novel Biomarker for Predicting Recurrence of Skull Base Chordoma. Frontiers in Oncology, 2021, 11, 698497.	2.8	9
21	Expression of Transforming Growth Factor $\hat{l}^2 l$, Smad3, and Phospho-Smad3 in Somatotropinomas and Their Relationship to Tumor Behavior. World Neurosurgery, 2021, 153, e20-e27.	1.3	4
22	Loss of SMARCB1 promotes autophagy and facilitates tumour progression in chordoma by transcriptionally activating ATG5. Cell Proliferation, 2021, 54, e13136.	5. 3	9
23	Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype. Aging, 2021, 13, 1276-1293.	3.1	7
24	Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors. Aging, 2021, 13, 1422-1439.	3.1	2
25	Clinical Analysis of Risk Factors of Postoperative Psychiatric Disorders in Patients With Adult Craniopharyngioma. Frontiers in Neurology, 2021, 12, 754349.	2.4	3
26	Prediction of Post-operative Visual Deterioration Using Visual-Evoked Potential Latency in Extended Endoscopic Endonasal Resection of Craniopharyngiomas. Frontiers in Neurology, 2021, 12, 753902.	2.4	0
27	Prognostic Utility of Optical Coherence Tomography for Visual Outcome After Extended Endoscopic Endonasal Surgery for Adult Craniopharyngiomas. Frontiers in Oncology, 2021, 11, 764582.	2.8	1
28	High Red Cell Distribution Width Independently Predicts Adverse Survival in Patients with Newly Diagnosed Skull Base Chordoma. OncoTargets and Therapy, 2021, Volume 14, 5435-5445.	2.0	2
29	A modified endovascular treatment protocol for iatrogenic internal carotid artery injuries following endoscopic endonasal surgery. Journal of Neurosurgery, 2020, 132, 343-350.	1.6	31
30	Brain Morphometric and Functional Magnetic Resonance Imaging Study on Patients with Visual Field Defects Resulting from Suprasellar Tumors: Preoperative and Postoperative Assessment. World Neurosurgery, 2020, 134, e353-e359.	1.3	5
31	Mean platelet volume and platelet distribution width serve as prognostic biomarkers in skull base chordoma: a retrospective study. BMC Cancer, 2020, 20, 988.	2.6	11
32	Contrahemispheric Cortex Predicts Survival and Molecular Markers in Patients With Unilateral High-Grade Gliomas. Frontiers in Oncology, 2020, 10, 953.	2.8	1
33	<p>Prognostic Value of Cumulative Score Based on Preoperative Fibrinogen and Albumin Level in Skull Base Chordoma</p> . OncoTargets and Therapy, 2020, Volume 13, 8337-8346.	2.0	9
34	JAG1, Regulated by microRNA-424-3p, Involved in Tumorigenesis and Epithelial–Mesenchymal Transition of High Proliferative Potential-Pituitary Adenomas. Frontiers in Oncology, 2020, 10, 567021.	2.8	9
35	Somatic SF3B1 hotspot mutation in prolactinomas. Nature Communications, 2020, 11, 2506.	12.8	38
36	MRI Signal Intensity and Electron Ultrastructure Classification Predict the Long-Term Outcome of Skull Base Chordomas. American Journal of Neuroradiology, 2020, 41, 852-858.	2.4	5

#	Article	IF	Citations
37	Structural and Functional Alterations in the Contralesional Medial Temporal Lobe in Glioma Patients. Frontiers in Neuroscience, 2020, 14, 10.	2.8	23
38	Application of endoscopic endonasal approach in skull base surgeries: summary of 1886 cases in a single center for 10 consecutive years. Chinese Neurosurgical Journal, 2020, 6, 21.	0.9	4
39	The role of serum growth hormone and insulin-like growth factor-1 in adult humans brain morphology. Aging, 2020, 12, 1377-1396.	3.1	8
40	Structural plasticity of the bilateral hippocampus in glioma patients. Aging, 2020, 12, 10259-10274.	3.1	8
41	LncRNA and mRNA expression profiles reveal the potential roles of lncRNA contributing to regulating dural penetration in clival chordoma. Aging, 2020, 12, 10809-10826.	3.1	3
42	CDKN2A (p16INK4A) affects the anti‑tumor effect of CDK inhibitor in somatotroph adenomas. International Journal of Molecular Medicine, 2020, 47, 500-510.	4.0	5
43	Clinical and Radiologic Characteristics, Surgical Outcomes, and Its Possible Origins of Chondroma of the Dural Convexity. BioMed Research International, 2020, 2020, 1-10.	1.9	2
44	A Series of 62 Skull Base Chordomas in Pediatric and Adolescent Patients: Clinical Characteristics, Treatments, and Outcomes. Neurology India, 2020, 68, 1030.	0.4	5
45	Predictive Value of Transforming Growth Factor-α and Ki-67 for the Prognosis of Skull Base Chordoma. World Neurosurgery, 2019, 129, e199-e206.	1.3	8
46	CCNB1 affects cavernous sinus invasion in pituitary adenomas through the epithelial–mesenchymal transition. Journal of Translational Medicine, 2019, 17, 336.	4.4	16
47	The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma. Journal of Translational Medicine, 2019, 17, 354.	4.4	10
48	The Apoptosis Regulator 14-3-3η and Its Potential as a Therapeutic Target in Pituitary Oncocytoma. Frontiers in Endocrinology, 2019, 10, 797.	3.5	10
49	Identification of a novel somatic mutation of <i>POU6F2</i> by wholeâ€genome sequencing in prolactinoma. Molecular Genetics & mp; Genomic Medicine, 2019, 7, e1022.	1.2	12
50	Metabolic profiling reveals distinct metabolic alterations in different subtypes of pituitary adenomas and confers therapeutic targets. Journal of Translational Medicine, 2019, 17, 291.	4.4	9
51	DAPT, a \hat{I}^3 -Secretase Inhibitor, Suppresses Tumorigenesis, and Progression of Growth Hormone-Producing Adenomas by Targeting Notch Signaling. Frontiers in Oncology, 2019, 9, 809.	2.8	31
52	Immunohistochemical Study of NR2C2, BTG2, TBX19, and CDK2 Expression in 31 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas. International Journal of Endocrinology, 2019, 2019, 1-8.	1.5	7
53	Increased resting-state functional connectivity in suprasellar tumor patients with postoperative visual improvement. International Journal of Medical Sciences, 2019, 16, 1245-1253.	2.5	4
54	Differential Diagnosis and Treatment Modality of Parasellar Plasmacytoma: Clinical Series and Literature Review. World Neurosurgery, 2019, 122, e978-e988.	1.3	7

#	Article	IF	CITATIONS
55	Expression of Cyclin E/Cdk2/p27Kip1 in Growth Hormone Adenomas. World Neurosurgery, 2019, 121, e45-e53.	1.3	7
56	Attenuation of EGFL7 Expression Inhibits Growth Hormone–Producing Pituitary Adenomas Growth and Invasion. Human Gene Therapy, 2018, 29, 1396-1406.	2.7	6
57	Aberrant Expression of Extracellular Signal-Regulated Kinase and 15-Hydroxyprostaglandin Dehydrogenase Indicates Radiation Resistance and Poor Prognosis for Patients with Clival Chordomas. World Neurosurgery, 2018, 115, e146-e151.	1.3	7
58	P21Waf1/Cip1 and p27Kip1 are correlated with the development and invasion of prolactinoma. Journal of Neuro-Oncology, 2018, 136, 485-494.	2.9	4
59	Analysis of clinical factors and PDGFR- \hat{l}^2 in predicting prognosis of patients with clival chordoma. Journal of Neurosurgery, 2018, 129, 1429-1437.	1.6	19
60	Enhancement of mitochondrial biogenesis and paradoxical inhibition of lactate dehydrogenase mediated by 14â€3â€3η in oncocytomas. Journal of Pathology, 2018, 245, 361-372.	4.5	17
61	Non-invasive radiomics approach potentially predicts non-functioning pituitary adenomas subtypes before surgery. European Radiology, 2018, 28, 3692-3701.	4.5	58
62	Neuroendoscopic Fenestration for Entrapped Temporal Horn After Surgery: Report of 3 Cases. World Neurosurgery, 2018, 112, 77-80.	1.3	6
63	Application of endoscopic third ventriculostomy for treating hydrocephalus-correlated Chiari type I malformation in a single Chinese neurosurgery centre. Neurosurgical Review, 2018, 41, 249-254.	2.4	17
64	SNF5 as a prognostic factor in skull base chordoma. Journal of Neuro-Oncology, 2018, 137, 139-146.	2.9	14
65	Epithelial–Mesenchymal Transition Induced by SMAD4 Activation in Invasive Growth Hormone-Secreting Adenomas. Open Chemistry, 2018, 16, 571-582.	1.9	3
66	Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion. Open Chemistry, 2018, 16, 621-626.	1.9	1
67	Integration of Proteomics and Metabolomics Revealed Metabolite–Protein Networks in ACTH-Secreting Pituitary Adenoma. Frontiers in Endocrinology, 2018, 9, 678.	3.5	25
68	A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma. Oncology Reports, 2018, 41, 113-124.	2.6	9
69	Association of TGF- \hat{I}^21 and WIF1 Expression with 36 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas: A High-Throughput Tissue Microarrays Immunohistochemical Study. World Neurosurgery, 2018, 119, e23-e31.	1.3	4
70	Functions and Mechanisms of Tumor Necrosis Factor-α and Noncoding RNAs in Bone-Invasive Pituitary Adenomas. Clinical Cancer Research, 2018, 24, 5757-5766.	7.0	43
71	Circular RNA In Invasive and Recurrent Clinical Nonfunctioning Pituitary Adenomas: Expression Profiles and Bioinformatic Analysis. World Neurosurgery, 2018, 117, e371-e386.	1.3	19
72	Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas. Journal of Neuro-Oncology, 2017, 132, 199-206.	2.9	18

#	Article	IF	Citations
73	Upregulation of cyclin B1 plays potential roles in the invasiveness of pituitary adenomas. Journal of Clinical Neuroscience, 2017, 43, 267-273.	1.5	20
74	Prognostic Value of a Category Based on Electron Microscopic Features of Clival Chordomas. World Neurosurgery, 2017, 99, 282-287.	1.3	4
75	Alterations of regional homogeneity and functional connectivity in pituitary adenoma patients with visual impairment. Scientific Reports, 2017, 7, 13074.	3.3	12
76	Long non-coding RNA C5orf66-AS1 is downregulated in pituitary null cell adenomas and is associated with their invasiveness. Oncology Reports, 2017, 38, 1140-1148.	2.6	30
77	EGFL7 participates in regulating biological behavior of growth hormone–secreting pituitary adenomas via Notch2/DLL3 signaling pathway. Tumor Biology, 2017, 39, 101042831770620.	1.8	32
78	Global expression profile of tumor stem-like cells isolated from MMQ rat prolactinoma cell. Cancer Cell International, 2017, 17, 15.	4.1	13
79	Differences in Dural Penetration of Clival Chordomas Are Associated with Different Prognosis and Expression of Platelet-Derived Growth Factor Receptor-β. World Neurosurgery, 2017, 98, 288-295.	1.3	21
80	Clinical Features and Prognostic Factors of Children and Adolescents with Clival Chordomas. World Neurosurgery, 2017, 98, 323-328.	1.3	17
81	Increased \hat{I}^2 -catenin and c-myc expression predict aggressive growth of non-functioning pituitary adenomas: An assessment using a tissue microarray-based approach. Molecular Medicine Reports, 2017, 15, 1793-1799.	2.4	13
82	Genome-wide analysis of differentially expressed lncRNAs and mRNAs in primary gonadotrophin adenomas by RNA-seq. Oncotarget, 2017, 8, 4595-4606.	1.8	23
83	Smad3 and phospho-Smad3 are potential markers of invasive nonfunctioning pituitary adenomas. OncoTargets and Therapy, 2016, 9, 2265.	2.0	13
84	Use of micro-positron emission tomography with 18F-fallypride to measure the levels of dopamine receptor-D2 and 18F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats. OncoTargets and Therapy, 2016, 9, 2057.	2.0	2
85	Assessment of sFRP4 as a bio-marker for predicting aggressiveness and recurrence of growth hormone-secreting pituitary adenomas. Oncology Reports, 2016, 35, 2991-2999.	2.6	3
86	Intraoperative Hemorrhage in Ventriculoscopic Surgery: Experience of a Single Chinese Neurosurgery Center. World Neurosurgery, 2016, 88, 548-551.	1.3	7
87	Solitary subdural osteoma: A case report and literature review. Oncology Letters, 2016, 12, 1023-1026.	1.8	7
88	The role of FSCN1 in migration and invasion of pituitary adenomas. Molecular and Cellular Endocrinology, 2016, 419, 217-224.	3.2	40
89	Classification and surgical approaches for transnasal endoscopic skull base chordoma resection: a 6-year experience with 161 cases. Neurosurgical Review, 2016, 39, 321-333.	2.4	43
90	Assessment of endoscopic treatment for quadrigeminal cistern arachnoid cysts: A 7-year experience with 28 cases. Child's Nervous System, 2016, 32, 647-654.	1.1	21

#	Article	IF	CITATION
91	Phosphorylation of kinase insert domain receptor by cyclin-dependent kinase 5 at serine 229 is associated with invasive behavior and poor prognosis in prolactin pituitary adenomas. Oncotarget, 2016, 7, 50883-50894.	1.8	16
92	Surgical resection of unilateral thalamic tumors in adults: approaches and outcomes. BMC Neurology, 2015, 15, 229.	1.8	32
93	Identification of Differentially Expressed Genes in Pituitary Adenomas by Integrating Analysis of Microarray Data. International Journal of Endocrinology, 2015, 2015, 1-7.	1.5	19
94	The role of TGF- \hat{l}^2 /Smad signaling in dopamine agonist-resistant prolactinomas. Molecular and Cellular Endocrinology, 2015, 402, 64-71.	3.2	34
95	Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas. BMC Cancer, 2015, 15, 272.	2.6	34
96	Overexpression of the cell adhesion molecule claudin-9 is associated with invasion in pituitary oncocytomas. Human Pathology, 2014, 45, 2423-2429.	2.0	18
97	Effects of fulvestrant on biological activity and Wnt expression in rat GH3 cells. Neural Regeneration Research, 2012, 7, 283-9.	3.0	1
98	Effects of fulvestrant, an estrogen receptor antagonist, on MMQ cells and its mechanism. Neuroendocrinology Letters, 2009, 30, 268-74.	0.2	7